SAMe (S-Adenosylmethionine)

SAMe is one of the better-evidenced consumer supplements for both mood support and joint comfort, with two important asterisks: it is genuinely contraindicated in bipolar disorder, and combining it with serotonergic medication is a real-world serotonin-syndrome risk. As an endogenous methyl donor synthesized from methionine and ATP, it participates in roughly 40 methylation reactions, including monoamine neurotransmitter synthesis and the production of phosphatidylcholine and glutathione. The pharmacology is plausible and the human trial base is unusually long for a supplement, starting in Italy in the 1970s where SAMe is still sold as a prescription pharmaceutical.

For mood support, the AHRQ 2002 evidence report from the University of Maryland synthesized 47 trials and concluded SAMe was significantly better than placebo and comparable in efficacy to tricyclic antidepressants. A 2009 Cochrane review by Rutjes covered both indications and was supportive. The single best-conducted modern trial is Papakostas 2010 in the American Journal of Psychiatry: 73 SSRI non-responders with major depressive disorder were randomized to adjunctive SAMe 800mg twice daily or placebo for 6 weeks, and the SAMe arm showed significantly greater response (36% vs 18%) and remission (26% vs 12%) rates. The 2016 Cochrane review by Galizia concluded the evidence was limited by small studies and high heterogeneity, but the direction across reviews has stayed consistent.

For osteoarthritis of the knee and hip, multiple older Italian trials and one mid-size American head-to-head trial support SAMe as roughly equivalent to NSAIDs in symptom relief with a slower onset. Najm 2004 in BMC Musculoskeletal Disorders randomized 56 OA patients to SAMe 1200mg/day or celecoxib 200mg/day for 16 weeks crossover: celecoxib worked faster, but by the end of the trial pain scores were statistically indistinguishable. A 2009 Cochrane review found low-quality but suggestive evidence of pain and function improvement. Treat the OA story as "modest, real, slow-onset, NSAID-comparable" rather than dramatic.

For fibromyalgia, two small Italian trials by Tavoni in 1987 and 1998 showed improvements in tender points and depressive symptoms vs placebo. The sample sizes are tiny and the trials are old, so this is a reasonable secondary indication rather than a primary reason to buy.

Italy uses oral and IV SAMe as a pharmaceutical for intrahepatic cholestasis (including the cholestasis of pregnancy), but the oral evidence for liver indications is weaker than the marketing suggests, and US framing should stay structure/function.

Critical safety: SAMe can trigger mania or hypomania in bipolar individuals and should never be recommended without screening for personal or family history of bipolar disorder. Combining SAMe with SSRIs, SNRIs, MAOIs, triptans, tramadol, or other serotonergic drugs carries a real serotonin-syndrome risk and should only be done under physician supervision (the Papakostas trial did this in a monitored setting).

Practical bottom line: 400mg twice daily on an empty stomach, with a foil-blistered enteric-coated tablet (Nature Made, Doctor's Best, Jarrow, NOW, or Source Naturals; all are licensed users of pharma-grade SAMe). Give it 4-6 weeks for mood, 8-12 weeks for joint comfort. Skip if you have bipolar disorder or take any serotonergic medication.